Express Scripts’ Cost Cap For PCSK9s Applicable To Other Drugs, PBM Says
Executive Summary
If PCSK9 spending by Express Scripts clients surpasses the $750m limit set for 2016, the PBM will pick up the excess cost, under a novel drug management arrangement for Repatha and Praluent.
You may also be interested in...
Express Scripts Diabetes Program Caps Drug Costs, Targets Adherence
New PBM management program aims to cut in half the projected increases in diabetes drug spending in 2017, improve patient adherence rates by 5%.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.